Humanin Peptide Research: Mitochondrial-Derived Cytoprotection, STAT3/BAX Signaling, and Preclinical Neuroprotective Evidence

Humanin is a 24-amino acid mitochondrial-derived peptide (MDP) that functions as an endogenous cytoprotective signaling molecule, operating through both intracellular apoptosis suppression and extracellular receptor-mediated survival pathways. First identified in 2001 from a functional screen of surviving neurons in Alzheimer’s disease brain tissue, humanin has since emerged as one of the most extensively studied MDPs in preclinical neuroscience, cardiology, and aging research. Its dual mechanism of action, binding the pro-apoptotic protein BAX intracellularly while activating JAK2/STAT3 signaling through a trimeric cell-surface receptor, distinguishes it from conventional neuroprotective peptides that operate through single-pathway mechanisms.

Discovery and Molecular Identity

Humanin was discovered by Hashimoto and colleagues in 2001 through an expression cloning strategy designed to identify genes capable of rescuing neurons from amyloid-beta toxicity. Using a cDNA library constructed from the occipital cortex of an Alzheimer’s disease patient, the research team identified a 75-base pair open reading frame within the mitochondrial 16S ribosomal RNA gene that encoded a previously unrecognized peptide. This peptide, designated humanin, demonstrated the ability to suppress neuronal cell death induced by four distinct familial Alzheimer’s disease (FAD) mutant genes: V642I-APP, NL-APP, M146L-PS1, and N141I-PS2, as well as by amyloid-beta 1-43 fragments (Hashimoto et al., PNAS, 2001).

The peptide’s primary sequence (MAPRGFSCLLLLTSEIDLPVKRRA) contains 24 amino acids with a molecular weight of approximately 2.7 kDa. Humanin was the first identified member of what is now recognized as a broader family of mitochondrial-derived peptides, which also includes MOTS-c and the small humanin-like peptides (SHLPs 1-6). Unlike nuclear-encoded neuroprotective factors, humanin’s mitochondrial origin means its expression is directly linked to mitochondrial copy number, biogenesis, and cellular stress state, creating a feedback loop between organelle health and cytoprotective signaling.

Receptor Pharmacology and Extracellular Signaling

Humanin’s extracellular signaling operates through a heterotrimeric receptor complex composed of ciliary neurotrophic factor receptor alpha (CNTFR), cytokine receptor WSX-1 (IL-27 receptor alpha), and glycoprotein 130 (gp130). Binding of humanin to this receptor complex activates the JAK2/STAT3 signaling cascade, which is a well-characterized survival pathway in neurons, cardiomyocytes, and other cell types. A 2009 study by Hashimoto and colleagues in the Journal of Neuroscience Research confirmed that STAT3 phosphorylation is essential for humanin’s neuroprotective activity, as dominant-negative STAT3 constructs abolished the peptide’s ability to rescue neurons from amyloid-beta toxicity in cortical culture models (n=6 independent experiments, p<0.01).

Beyond STAT3, humanin also activates extracellular signal-regulated kinase 1/2 (ERK1/2) through this same receptor complex. Bhattacharya and colleagues demonstrated in a 2017 study published in Oncotarget that humanin activates ERK1/2, AKT, and STAT3 signaling pathways in hippocampal tissue, with age-dependent differences in signaling magnitude. Young mice (3 months) showed significantly greater ERK1/2 phosphorylation responses to humanin compared to aged mice (18 months), suggesting that receptor sensitivity or downstream pathway capacity declines with age.

Humanin also interacts with formyl peptide receptor-like 1 (FPRL1/FPR2) and FPRL2 (FPR3). These G-protein coupled receptors are expressed on immune cells and neural tissue, and their activation by humanin contributes to anti-inflammatory signaling. This receptor promiscuity gives humanin a broader signaling footprint than peptides restricted to single receptor targets.

Intracellular Anti-Apoptotic Mechanisms

Humanin’s intracellular cytoprotective activity operates through direct protein-protein interactions that are mechanistically distinct from its receptor-mediated signaling. The peptide binds directly to BAX, a pro-apoptotic BCL-2 family member, preventing BAX oligomerization and translocation to the mitochondrial outer membrane. This blocks the formation of mitochondrial permeability transition pores, preventing cytochrome c release and downstream caspase activation. A 2003 study by Guo and colleagues in Nature demonstrated that humanin physically associates with BAX in a co-immunoprecipitation assay and that this interaction is sufficient to prevent BAX-induced cell death in multiple cell lines (Guo et al., Nature, 2003).

Humanin also binds insulin-like growth factor binding protein 3 (IGFBP-3), a protein that promotes apoptosis independently of IGF-1 signaling. The humanin-IGFBP-3 interaction was characterized by Ikonen and colleagues in a 2003 PNAS study, which demonstrated that humanin neutralizes IGFBP-3’s pro-apoptotic activity in a dose-dependent manner across multiple cell types. The binding affinity between humanin and IGFBP-3 was measured at approximately 10 nM, indicating a physiologically relevant interaction that modulates the balance between cell survival and programmed death at the mitochondrial level.

The HNG Analogue: 1,000-Fold Potency Enhancement

Native humanin has relatively low potency in vivo, which led to the development of several synthetic analogues. The most widely studied is [Gly14]-humanin, designated HNG, which carries a serine-to-glycine substitution at position 14 of the peptide sequence. This single amino acid change increases cytoprotective and neuroprotective potency by approximately 1,000-fold compared to native humanin, making HNG the standard form used in virtually all in vivo preclinical research.

The potency enhancement from the S14G substitution appears to result from improved resistance to oxidative inactivation and enhanced receptor binding affinity. In cell-based assays, HNG protects against amyloid-beta-induced neuronal death at concentrations as low as 100 pM, whereas native humanin requires concentrations in the high nanomolar range for equivalent protection. This potency difference has been replicated across multiple research groups and cell systems, establishing HNG as the reference compound for humanin pharmacology studies.

Additional analogues include AGA-HNG, which combines the S14G substitution with additional modifications that confer resistance to dimerization, and colivelin, a hybrid peptide incorporating humanin’s active domain fused with activity-dependent neurotrophic factor (ADNF) sequences. These engineered variants expand the research toolkit available for investigating humanin’s signaling mechanisms in different disease models.

Preclinical Neuroprotection Data

The most extensive preclinical evidence for humanin involves neuroprotection against Alzheimer’s disease-relevant insults. Tajima and colleagues published a detailed characterization in 2019 in the journal Molecules (MDPI) examining humanin’s protective effects against multiple AD-relevant stressors. Their work confirmed that HNG protects cultured neurons against toxicity from amyloid-beta 25-35, amyloid-beta 1-42, and familial AD presenilin mutants, with EC50 values in the low picomolar to nanomolar range depending on the specific insult.

In vivo neuroprotection data comes from several mouse model studies. Niikura and colleagues demonstrated that intracerebroventricular administration of HNG in APP/PS1 transgenic mice reduced hippocampal neuronal loss and improved spatial memory performance in the Morris water maze test, with treated animals showing approximately 40% improvement in escape latency compared to vehicle-treated transgenic controls (n=10-12 per group, p<0.05). The memory improvements correlated with reduced amyloid plaque burden and decreased neuroinflammatory markers in treated animals.

Beyond Alzheimer’s models, humanin has shown neuroprotective effects in preclinical models of stroke (middle cerebral artery occlusion), traumatic brain injury, and prion-induced neurodegeneration. The consistent efficacy across multiple neurotoxic insult models supports the interpretation that humanin acts on a conserved downstream death pathway rather than on any single disease-specific mechanism.

Cardioprotective Research

Humanin’s cardioprotective properties have been investigated in both murine and porcine models of myocardial ischemia-reperfusion injury. Muzumdar and colleagues published a 2010 study in the American Journal of Physiology demonstrating that HNG administration (administered intraperitoneally at 2 mg/kg either 1 hour prior to or at the time of reperfusion) significantly reduced myocardial infarct size in a murine left coronary artery occlusion model. The treatment produced significant reductions in infarct area relative to the area at risk, with the mechanism attributed to AMPK activation and endothelial nitric oxide synthase (eNOS) phosphorylation.

A 2020 study by Sharp and colleagues in JACC: Basic to Translational Science extended these findings to a porcine model, which more closely recapitulates human cardiac physiology. In this large-animal study, HNG administration during ischemia-reperfusion injury significantly reduced infarct size and preserved left ventricular ejection fraction compared to vehicle-treated controls. The porcine model data is particularly valuable because pig heart anatomy, coronary circulation, and infarct healing patterns parallel human cardiac pathophysiology far more closely than rodent models.

Subsequent mechanistic work has shown that humanin’s cardioprotective effects involve STAT3-dependent upregulation of metallothionein, an endogenous antioxidant protein, combined with direct suppression of mitochondrial permeability transition through the BAX-binding mechanism described above. Yao and colleagues demonstrated in 2021 (Biochimica et Biophysica Acta) that humanin reduces mitochondrial reactive oxygen species production during reperfusion, prevents mitochondrial membrane potential collapse, and attenuates the calcium overload that drives cardiomyocyte death during ischemia-reperfusion.

Aging and Metabolic Healthspan

The relationship between circulating humanin levels and aging has become an active area of investigation. Circulating humanin concentrations decline with age in both humans and mice, with cross-sectional human studies showing approximately 40% lower plasma humanin levels in individuals over 70 compared to those under 40. This age-related decline parallels the reduction in mitochondrial DNA copy number and function that characterizes biological aging, consistent with humanin’s mitochondrial origin.

Cohen and colleagues published a landmark 2020 study in the journal Aging that directly tested whether humanin supplementation could modify lifespan and healthspan parameters. In C. elegans, humanin overexpression significantly extended lifespan in a daf-16/FOXO-dependent manner. In mice, twice-weekly HNG treatment of middle-aged animals (beginning at 18 months) produced measurable improvements in metabolic healthspan parameters including reduced visceral adiposity, preserved lean body mass, and decreased circulating inflammatory markers at 28 months of age (n=5 per group). Humanin transgenic mice displayed phenotypes overlapping with the worm results and showed increased protection against toxic insults, establishing cross-species conservation of humanin’s protective functions.

The insulin/IGF-1 signaling axis appears central to humanin’s metabolic effects. Lee and colleagues demonstrated that humanin improves insulin sensitivity in diet-induced obesity models through central (hypothalamic) STAT3 activation, reducing hepatic glucose output and improving peripheral glucose disposal. These metabolic effects are distinct from humanin’s direct cytoprotective actions and suggest the peptide operates as a systemic hormonal signal linking mitochondrial status to whole-organism metabolic regulation.

Key Research Findings

• Humanin is a 24-amino acid mitochondrial-derived peptide encoded within the 16S rRNA gene, first identified in 2001 from an Alzheimer’s disease neuroprotection screen (Hashimoto et al., 2001).
• The HNG analogue (S14G substitution) exhibits approximately 1,000-fold greater cytoprotective potency than native humanin, with neuroprotective EC50 values in the picomolar range.
• Extracellular signaling proceeds through a CNTFR/WSX-1/gp130 trimeric receptor complex activating JAK2/STAT3 and ERK1/2 pathways; intracellular protection involves direct BAX binding and IGFBP-3 neutralization (Guo et al., Nature, 2003; Ikonen et al., PNAS, 2003).
• In murine cardiac ischemia-reperfusion models, HNG (2 mg/kg IP) significantly reduced infarct size through AMPK-eNOS signaling (Muzumdar et al., 2010). Porcine model data confirmed these findings in large-animal cardiac physiology (Sharp et al., 2020).
• HNG treatment of middle-aged mice reduced visceral fat, preserved lean mass, and decreased inflammatory markers at 28 months (Cohen et al., Aging, 2020; n=5/group).
• Circulating humanin levels decline approximately 40% between young adulthood and age 70+ in cross-sectional human studies, correlating with reduced mitochondrial DNA copy number.
• Humanin overexpression extends lifespan in C. elegans through a daf-16/FOXO-dependent mechanism, with cross-species phenotypic conservation observed in transgenic mice (Cohen et al., 2020).
• No human intervention trials have been completed. All efficacy data derives from in vitro cell culture and in vivo animal models.

Analytical Considerations for Research-Grade Humanin

Humanin’s 24-amino acid sequence presents specific analytical challenges for purity verification. The peptide contains a single cysteine residue (Cys8) that is susceptible to oxidative dimerization during storage, which can reduce effective monomer concentration without appearing as a traditional impurity on HPLC analysis. Researchers working with humanin should verify that their certificate of analysis specifically addresses disulfide-linked dimer content in addition to standard HPLC purity metrics.

The molecular weight (approximately 2,687 Da for the free acid form) is well within the range for standard reversed-phase HPLC purity analysis and electrospray ionization mass spectrometry identity confirmation. Given the significant potency difference between native humanin and the HNG analogue, accurate sequence verification by mass spectrometry is essential to confirm whether a given lot contains native sequence or the S14G variant, as misidentification would produce dramatically different results in functional assays.

Proper storage conditions for lyophilized humanin include desiccated storage at -20°C or below, with reconstituted aliquots stored at -80°C to minimize oxidative degradation and cysteine-mediated aggregation. Single-use aliquoting is strongly recommended to avoid freeze-thaw-induced structural changes that could compromise research reproducibility.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

Maple Research Labs provides independently verified research peptides with third-party COA testing through Janoshik Analytical. All products ship same-day from Canada with batch-specific documentation. Browse our full research peptide catalog.

For peer-reviewed research on this topic, visit PubMed.